I
n the past decade, infliximab (IFX) use in the management of children with moderate-to-severe Crohn's disease (CD) and ulcerative colitis (UC) has increased exponentially. The success of IFX in clinical trials leaves no doubt as to its benefits, and indications for use have become standard for steroid-refractory, steroid-dependent, complicated, or severe inflammatory bowel disease (IBD). 1 However, studies also suggest that response rates diminish over time. [2] [3] [4] [5] As IFX is a chimeric anti-tumor necrosis factor (TNF) monoclonal antibody, individuals can develop loss of response (LOR) or an infusion reaction linked to acquisition of serum IFX antibodies (ATI) with decreasing levels of drug titers. [2] [3] [4] [5] Thus, a new debate has emerged as to how to optimize durable response rates with biologic therapies. Since the early studies which demonstrated that intermittent or "on-demand" IFX administration was associated with poorer sustained response rates, because of development of anti-IFX antibodies, 2,6,7 regular infusions of IFX have proven superior to episodic administration. 2, 8 The addition of concomitant immunomodulators (IMs), specifically purine antimetabolites in adult patients with CD, has been shown to reduce ATI and decrease clearance of IFX, resulting in higher IFX trough levels and sustaining steroid-free clinical remission. [9] [10] [11] Similarly, the superiority of methotrexate (MTX) in combination with TNF-alpha inhibitor has been observed in adult patients with rheumatoid arthritis. 12, 13 However, a recent study in adult patients with active CD who received induction prednisone therapy found that the combination of MTX and IFX was no more Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.ibdjournal.org).
effective than IFX alone for inducing and maintaining remission. 14 Notably, all included patients were intravenously premedicated with hydrocortisone to minimize the risk of infusion reaction and IFX sensitization. This additional interaction may have confounded the observed differences in outcomes between treatment groups. In contrast, a more recent study from the pediatric IBD Collaborative Research Group Registry suggested that MTX in male children with CD increased durability of IFX therapy compared with azathioprine (AZA). 11 Data on long-term durability of response to anti-TNF therapy in pediatric IBD beyond 1 year continue to emerge, but remain limited. 3, 5, 11, [15] [16] [17] [18] [19] [20] [21] [22] Moreover, reported outcomes are variable. 3, 5, 11, [15] [16] [17] [18] [19] [20] [21] [22] LOR was reported at a rate of 2% to 6% per year over 5 years in pediatric patients with luminal CD on IFX 22 to a cumulative probability of LOR of 17%, 38%, and 51% at 1, 3, and 5 years, respectively, in a cohort of predominantly patients with CD on IFX or adalimumab. 20 In a multicenter cohort study in children with moderate/severe UC, corticosteroid-free inactive disease was observed in 38% and 21% of patients at 12 and 24 months, respectively. The likelihood of avoiding colectomy at 2 years was 61%, and increased to 74% when patients receiving intermittent IFX treatment were excluded. 3 Although studies report that IM use (AZA, mercaptopurine [MP] , and MTX) in combination with anti-TNF therapy is common, 6, 10, [23] [24] [25] [26] [27] [28] limited data exist on the long-term benefit of concomitant therapy over IFX monotherapy in pediatric IBD. 5, 11, 22 Hence, the goal of this study was to retrospectively review the long-term efficacy of IFX therapy in a cohort of children with IBD, and to determine whether IFX in combination with an IM (AZA, 6 MP, or MTX) achieved greater long-term durability of response than IFX monotherapy. Secondary goals included assessing: (1) remission/response rates at 1-4 years follow-up between groups; (2) failure event rates during the treatment period; (3) average time to LOR; (4) reasons for discontinuation of therapy; (5) rates of initial corticosteroid use and time to discontinuation of corticosteroid therapy; (6) adverse event rates; and (7) alternative choices of therapy for patients who discontinued IFX.
MATERIALS AND METHODS

Study Design
British Columbia Children's Hospital (BCCH) is a tertiary/ quaternary care hospital that provides centralized care to the children with IBD within the province of British Columbia. A prospectively maintained, clinical pediatric IBD database at BCCH captures all patients with IBD diagnosed and/or clinically followed by the Gastrointestinal division. The diagnostic workup includes upper gastrointestinal endoscopy and ileocolonoscopy. Where indicated, patients are also investigated with magnetic resonance enterography and/or wireless capsule endoscopy. Disease location identified by these investigations is routinely recorded using definitions of macroscopic involvement as defined by the Paris classification. 29 Data on demographics, ethnicity, family history, age at diagnosis, IBD therapies, and duration of disease before IFX start are recorded. In addition, laboratory investigations, Pediatric Crohn's Disease Activity Index (PCDAI), Pediatric Ulcerative Colitis Activity Index (PUCAI), and physician global assessment (PGA) are recorded at each IFX infusion visit.
All children with IBD (CD or UC) who received treatment with IFX between January 2002 and December 2014 were identified. Patients with IBD were included in the study if they underwent IFX induction before 18 years of age and were followed up for a minimum of 1 year. Patients were excluded from the study if they received treatment with previous biologic therapy (i.e., adalimumab), or intermittent (on demand) IFX therapy, had followup of less than 12 months, or had grossly incomplete charts. The number of children with IBD-U that met the study criteria was too low to warrant inclusion and separate analysis. Data extracted for analysis included, sex, disease type (CD or UC), disease location, complicating features of disease (i.e., fistulas and strictures), extraintestinal manifestations (i.e., joint disease and erythema nodosum), date of diagnosis, age at diagnosis, date of IFX start, age at IFX start, dosage and dosing schedule of IFX, concurrent medications (AZA, 6 MP, MTX, corticosteroids, 5-aminosalicylic acid (5-ASA), antibiotics) at induction and at 6 months 1, 2, 3, and 4 years follow-up, duration of concurrent medication use (where applicable), PCDAI, PUCAI, and PGA before induction, postinduction, at 6 months, 1, 2, 3, and 4 years, or until study completion. Additional data on IFX use included date of IFX discontinuation, total number of IFX infusions, duration of treatment (months), duration of follow-up (months), reason for discontinuation, date of IFX, and side effects while on IFX.
The status of a patient's outcome was defined as, response, remission, or secondary LOR. PGA was defined as inactive, mild, moderate, or severe disease. Response was defined as a decrease of $15 points on the PCDAI or PUCAI from baseline, a PGA of mild disease or remission (PCDAI #10, PUCAI #10), and a PGA of inactive disease. Primary nonresponse was defined as a PGA of ongoing active moderate-tosevere disease or failure of the PCDAI or PUCAI to decrease $15 points from baseline with induction doses. Secondary LOR was defined as recurrence of a moderate-to-severe PGA because of the patients' underlying inflammatory disease or a PCDAI or PUCAI .30 at any point after induction doses, resulting in discontinuation of IFX by the treating physician. Dose escalation (dose increase in mg/kg or shortening of infusion interval or both) with regaining of response was considered as ongoing drug response. Where disease activity index scores could not be formally calculated in patients at a particular visit, the preceding and subsequent treatment visits were used to provide an estimate of the response/remission rate. Response after induction, and remission, response at 6 months, 1, 2, 3, and 4 years were determined. In addition, the ability to discontinue corticosteroids, requirement for escalation of IFX dosing or frequency, average time to IFX LOR, reason for discontinuation, and fate of IFX (i.e., medication changes and surgery rates) were evaluated. Lastly, all adverse events were documented in each therapy regime (IFX monotherapy versus combination therapy) and by underlying IBD diagnosis.
Statistical Analysis
Demographics
Continuous variables were reported as either medians with interquartile range (IQR) or mean 6 SD depending on the data approximation to normal distribution, and discrete variables were reported as counts and proportions.
Induction Response
A binary logistic regression model was used to assess potential predictors of postinduction response to IFX therapy. This test was performed for the overall population as well as for CD and UC subgroups. Variables that were assessed include sex, diagnosis, ethnicity, presence of extraintestinal manifestations (joint disease and erythema nodosum), corticosteroid use at induction, IM use at induction, age at diagnosis, age at induction, time from diagnosis to induction, baseline C-reactive protein (CRP) levels, and baseline disease activity index.
Long-term Response
Secondary LOR was explored using a Cox proportional hazards model in the CD and UC subgroups. Induction failures were excluded from analysis. Variables that demonstrated an association during univariate screening (P , 0.2) were included in a multivariate model with our primary variable, IM use. Variables included in the analysis were sex, ethnicity, age at diagnosis, disease location, presence of perianal disease, presence of small bowel disease, presence of complicating disease behavior, presence of extraintestinal manifestations (joint disease and erythema nodosum), time from diagnosis to induction, corticosteroid use at induction, antibiotic use at induction, and IM use at induction. The effect of IM use on primary outcomes was further investigated using a chi-square test of proportions between treatment groups.
Propensity Score Matching
Propensity score matching was used to compare primary outcomes in the IFX monotherapy and combination therapy groups within the CD population. Forty-one CD monotherapy patients were matched with 41 CD combination therapy patients using the nearestneighbor matching algorithm. Multiple imputation was used to fill in missing values for disease activity and CRP levels before propensity score matching could be implemented. Propensity scores were calculated based on the following variables: sex, ethnicity, baseline disease activity, baseline CRP, age at induction, disease extent, disease behavior, presence of perianal disease, joint involvement, and corticosteroid use at induction. Similarity of the 2 groups was assessed using a student's t test or Mann-Whitney U test for continuous data depending on whether the data followed the normal distribution, and a chi-square test of proportions for nominal data. A chi-square test of proportions was also used to compare outcomes of the 2 groups including remission at 1 year, remission at 2 years, and LOR at any time of follow-up.
In the propensity score-matched groups, Kaplan-Meier analysis was used to estimate the durability of response to IFX during multiple time points over the entire course of follow-up. Time to event was analyzed from the date of anti-TNFa initiation until the date of LOR to drug or last known follow-up. Primary comparisons were made between survival function estimates for patients receiving IFX monotherapy versus combination therapy. The log-rank test was used to evaluate whether the difference in ongoing IFX response was statistically different, with the null hypothesis being there was no difference in continued response between the 2 treatment regimes.
All reported P values are 2 sided. P values , 0.05 were considered significant. Data were analyzed using SPSS (version 22.0, SPSS, Inc, Chicago, IL).
Ethical Considerations
Ethical approval for the study was obtained from the University of British Columbia Clinical Research Ethics Board and the British Columbia Children's and Women's Research Review Committee.
RESULTS
Study Population
One hundred and eighty-one children and adolescents with IBD who received IFX between January 2002 and December 2014 were identified. Thirty-three patients were excluded because of intermittent IFX dosing (n ¼ 3), previous biologic experience (n ¼ 9), inadequate follow-up of ,1 year (n ¼ 3), incomplete charts (n ¼ 14), and postoperative IFX initiation (n ¼ 4). One hundred and forty-eight patients were included: 54% male, median age at diagnosis of 11.92 years (IQR, 10.02-13.97), 113 patients with CD (76%), and 35 (24%) with UC. Patient demographics, disease characteristics, and phenotype are summarized in Tables 1-3. Ninety (61%) patients with IBD were on IMs (64% CD, 51% UC), 58 (39%) on AZA (38% CD, 43% UC), 9 (6%) on 6-MP (8% CD, 0% UC), 23 (16%) MTX (18% CD, 9% UC), for a period of at least 6 months postinduction. The remaining 58 (39%) patients (36% CD, 49% UC) were initiated on IFX monotherapy. At IFX initiation, 67 patients (45%) were on corticosteroids. A significantly higher proportion of patients with UC were on corticosteroids at IFX induction (69% versus 38%, P ¼ 0.002) because of severe disease.
The median PCDAI and PUCAI at IFX initiation were 32. 
Induction Response
Based on disease activity scores and PGA, the response rate to IFX induction for all patients was 91% (134/148), with a 95% response for CD (107/113) compared with 77% for UC (27/35) (See Table S1 , Supplemental Digital Content 1, http://links.lww. com/IBD/B625). Treatment duration was similar in patients who responded to IFX induction therapy with a median duration of therapy of 25.4 months (IQR, 14.7-38.2 months). Covariates tested for significant association with response to induction therapy are listed in Table S2 (Supplemental Digital Content 2, http:// links.lww.com/IBD/B626). CD was found to be a positive predictor of response to induction therapy (odds ratio ¼ 2.63, 95% confidence interval [CI], 1.01-6.85, P ¼ 0.048).
This analysis was repeated for the CD population subgroup (n ¼ 113) and UC population subgroup (n ¼ 35) including disease extent and behavior and revealed no significant predictors of induction response in the CD group. However, in the UC population, AZA use was found to be positively associated with response to induction dosing (P ¼ 0.041). Of the primary nonresponders with CD, 67% (4/6) were on IFX monotherapy and all patients required intestinal resection. Similarly, 75% (6/8) of patients with UC who failed IFX induction therapy were on IFX monotherapy (6 underwent colectomy, 1 responded to adalimumab, and 1 was started on 6-MP). A group of 69 patients had both CRP and erythrocyte sedimentation rate (ESR) results from IFX start available for further analysis. Median levels of CRP and ESR, respectively, were significantly higher in the group that experienced a response to induction (25.0 mm/h versus 8.5 mg/L, P ¼ 0.008; 42.0 versus 31.0, P ¼ 0.036).
Long-term Response
Crohn's Disease Among responders to IFX induction, subsequent secondary LOR necessitating other therapy was experienced by 24 patients with CD (13 on monotherapy and 11 on combination therapy) in a linear fashion at an average per annum rate of 9.07% (9.73% for luminal patients with CD). Of the 13 patients on monotherapy who experienced secondary LOR, 4 (31%) required surgical intervention, 5 (38%) subsequently initiated adalimumab, 2 (15%) were transitioned to AZA, 1 (7%) was rescued with corticosteroids, and 1 (7%) required an autologous bone marrow transplant to treat an underlying autoimmune neutropenia condition. Of the 11 patients who experienced secondary LOR in the combination therapy group, 4 (36%) required surgical intervention, and 7 (64%) subsequently initiated adalimumab. The median time to discontinuation or otherwise end of followup was 26.9 months (IQR 16.1-39.5). Continued response was seen in 87% (93/107) of patients at 6 months, 82% (82/100) at 1 year, 82% (65/79) at 2 years, 87% (45/52) at 3 years, and 82% (23/28) at 4 years (see Table S1 , Supplemental Digital Content 1, http://links.lww.com/ IBD/B625). Remission was observed in 72% (77/107) of patients at 6 months, 68% (68/100) of patients at 1 year, 73% (59/79) at 2 years, 79% (41/52) at 3 years, and 82% (23/28) at 4 years (see Table S1 , Supplemental Digital Content 1, http://links.lww.com/IBD/B625).
Excluding induction failures (n ¼ 6) from the analysis, a Cox proportional hazards model was used to assess the association of key variables with secondary LOR over time. The only variable that was found to be associated with a reduced hazard of secondary LOR was combination therapy with IM for greater than 6 months (hazard ratio ¼ 0.39, 95% CI, 0.17-0.88, P ¼ 0.025). No difference in outcomes was observed between patients with CD naive to IM at induction and those following a step-up treatment approach (P ¼ 0.842). Univariable and multivariable associations are summarized in Table 4 , and survival curves for monotherapy and combination therapy groups are compared in Figure 1A .
In addition, when the sample was restricted to patients with luminal disease only (n ¼ 101), combination therapy was again found to reduce the hazard of secondary LOR (hazard ratio ¼ 0.41, 95% CI, 0.18-0.91, P ¼ 0.029).
Ulcerative Colitis
Among responders to IFX induction, subsequent secondary LOR necessitating other therapy was experienced by 6 patients with UC in a linear fashion at an average per annum rate of 8.3%. The median time to discontinuation or otherwise end of follow-up was 22.8 months (IQR 10.8-30.8). Continued response was observed in 56% (15/27) of patients at 6 months, 67% (16/24) at 1 year, 83% (15/ 18) at 2 years, 88% (7/8) at 3 years, and 100% (2/2) at 4 years (see Table S1 , Supplemental Digital Content 1, http://links.lww.com/IBD/ B625). Remission was observed in 56% (15/27) of patients at 6 months, 67% (16/24) at 1 year, 72% (13/18) at 2 years, 75% (6/8) at 3 years, and 100% (2/2) at 4 years (see Table S1 , Supplemental Digital Content 1, http://links.lww.com/IBD/B625).
Of the 4 patients on monotherapy who experienced secondary LOR, 2 (50%) required surgical intervention, 1 (25%) was transitioned to AZA, and 1 (25%) was continued on 5-ASA because of a psoriasis condition. One of the 2 patients who suffered secondary LOR in the combination therapy group one required surgical intervention, whereas the other subsequently initiated adalimumab.
Similar to the CD population, a Cox proportional hazards model was constructed excluding induction failures (n ¼ 8) from analysis. In contrast to the CD population, no variables were associated with a reduced hazard of secondary LOR. No difference in outcomes was observed between patients with UC naive to IM induction and those following a step-up treatment approach (P ¼ 0.641). Univariable associations are summarized in Table 5 , and survival curves for monotherapy and combination therapy groups are compared in Figure 1B .
Therapy Details and Dose Intensification Outcomes
Crohn's disease follow-up period. Similarly, 25 (36%) patients with CD on combination therapy who responded to induction were escalated to a dose of 10 mg/kg at some point during their follow-up. Moreover, the mean interval between infusions at conclusion of follow-up was 6.74 6 1.38 weeks for the monotherapy group compared with 6.91 6 1.43 weeks in the combination therapy group (P ¼ NS). Corticosteroids were used during IFX induction for 43 patients with CD (38%). Four patients (9%) on corticosteroids were primary nonresponders. Of the remaining 39 patients, the mean time to corticosteroid discontinuation was 7.75 weeks (range 1-19 weeks). Twenty-nine patients (74%) had ongoing response to IFX maintenance therapy, whereas 10 (26%) eventually discontinued IFX therapy (range 2-17 months).
Ulcerative Colitis
Of the patients with UC who responded to IFX induction therapy, only 8 (30%) remained on standard IFX dosing during the course of therapy. In contrast, 19 (70%) of patients (9 [82%] on monotherapy, 10 [63%] on combination therapy) required dose or frequency escalation during the course of therapy to maintain response/remission. Of the 19 patients in whom dose intensification was implemented, recapturing of response with control of symptoms was established in 12 (63%), whereas 7 (37%) discontinued the drug, 6 as a result of secondary LOR, and 1 because of a severe infusion reaction. Dose intensification was not attempted in 2 patients because of infusion reactions that required discontinuation of therapy.
Among primary responders on monotherapy, 5 patients with UC (46%) required an increase in dose to 10 mg/kg over the follow-up period. Similarly, 10 (63%) patients with UC on combination therapy who responded to induction were escalated to a dose of 10 mg/kg at some point during their follow-up. Moreover, the mean interval between infusions at conclusion of follow-up was 6.22 6 1.64 weeks for the monotherapy group compared with 6.60 6 1.64 weeks in the combination therapy group (P ¼ NS).
Corticosteroids were used during IFX induction for 24 patients with UC (69%). Seven patients (30%) on corticosteroids were primary nonresponders. Of the remaining 17 patients, the mean time to corticosteroid discontinuation was 9.19 weeks (range 4-14 weeks). Ten patients (59%) had ongoing response to maintenance IFX therapy, whereas 7 (41%) eventually discontinued IFX therapy (range 3-25 months). 
IM Use and Concomitant Therapy
Adverse Events
IFX was generally well tolerated by patients (see Table S3 , Supplemental Digital Content 3, http://links.lww.com/IBD/B627). Overall, 56 (37.8%) patients had no documented adverse event while on therapy. In those who had at least one documented adverse event during treatment, there was no difference between patients on IFX monotherapy (67.2%) versus IM combination therapy (60.0%). The most common adverse events were upper respiratory tract infections, minor skin infections, and gastroenteritis. Twelve patients had infusion reactions, 7 of which required discontinuation of therapy. Clostridium difficile cytotoxin was detected in 6% of cases experiencing symptom exacerbation; however, all responded to antibiotic treatment. There were 3 serious systemic infections (2 sepsis/bacteremia and 1 meningitis), 2 of which occurred in patients on IFX monotherapy and 1 in patients receiving combination therapy. One male patient on concomitant therapy with IFX and AZA was diagnosed with a follicular lymphoma. He initially presented with severe perianal CD and erythema nodosum at age 6 and was diagnosed with a follicular lymphoma isolated to a left preauricular lymph node at age 15. At age 13, he was placed on concomitant therapy with IFX (initiated on 5 mg/kg with dose escalation to 10 mg/kg after 7 months because of incomplete response) and AZA (2.5 mg/kg; 75 mg daily). The lymphoma was detected at 18 months from commencement of concomitant therapy, and 9 years from diagnosis. IFX and AZA were discontinued, and the tumor was fully excised without further intervention. He was subsequently placed on MTX, required exclusive enteral nutrition and prednisone, and at age 16 underwent a subtotal colectomy with end ileostomy for fibrostenotic disease. The patient did well after surgery and was transitioned to adult gastroenterology during his seventeenth year. At age 25, he continues to do well without tumor recurrence and working in the private sector. No deaths were reported during the study period.
Propensity Score Matching in CD
Propensity score matching was used to compare primary outcomes in the IFX monotherapy and combination therapy groups within the CD population. No significant differences in key indicators were found between the 2 groups (Table 7) . However, the monotherapy and combination therapy groups differed significantly in primary outcomes including remission at 1 year (P ¼ 0.020), remission at 2 years (P ¼ 0.044), and overall maintenance of response (P ¼ 0.001), summarized in Table 8 . In addition, the combination therapy group demonstrated a more durable response over time (P ¼ 0.022, Fig. 2 ).
DISCUSSION
The success of IFX in clinical trials and in clinical practice leaves no doubt as to its benefits, and indications for use have become standard for steroid-refractory, steroid-dependent, complicated, or severe pediatric and adult IBD. However, there is still limited data on the long-term durability of IFX in pediatric patients with IBD beyond 1 year. We presented a single-center experience with IFX in a well-characterized cohort of pediatric patients with IBD evaluating long-term durability, the impact of combination therapy with immune modulator, and safety of IFX. Consistent with published data, successful induction therapy in the CD cohort was associated with continued response in 82% and remission in 68% of patients at 1 year.
The present study showed that CD was a positive predictor of response to induction therapy (95% versus 77%), likely reflecting the confounding effect of disease severity and fecal loss of IFX in patients with UC. 30 Although a significantly higher proportion of patients with UC were on corticosteroids at IFX initiation (69% versus 38%), duration of corticosteroid use was similar and outcomes at 1 year were comparable with patients with CD with continued response in 88% and remission in 56% of patients with UC. Notably, of the primary nonresponders, 67% of patients with CD and 75% with UC were on IFX monotherapy, with AZA use in patients with UC shown to be positively associated with response to induction dosing. This observation suggests that at IFX initiation, concomitant therapy is beneficial, possibly through the effect on IFX levels. Furthermore, it is becoming increasingly evident that an accelerated IFX induction strategy for patients with acute severe UC will decrease the risk of primary nonresponse and need for colectomy. 31 Consistent with previous reports, 3,5 80% (28 of 35) and 74% (26 of 35) of patients with UC avoided colectomy at 1 and 2 years, respectively, after treatment with IFX.
In keeping with adult studies, 32 our study shows that baseline CRP levels were significantly higher in the group that experienced IFX induction response (25.0 versus 8.5 mg/L). Similarly, higher baseline ESR levels (42.0 versus 31.0 mm/h) predicted induction response. These findings suggest that the noninvasive inflammatory biomarkers are clinically useful when evaluating treatment options and can be used as biological markers when predicting IFX induction response. Intriguingly, a study by Magro et al showed that higher baseline CRP levels in an adult CD cohort were a predictor of primary nonresponse to IFX. 33 Although the reasons for the discrepancy between studies still need to be explored, it likely reflects the biological heterogeneity of the disease and suggests that evaluation of further novel biomarkers is needed to optimize treatment choice and response.
Our cohort also showed durability of IFX response with outcomes comparable with previous studies. 3, 5, 11, 15, 20, 22 Indeed, in both patients with CD and UC, continued response was seen in over 80% and remission in over 70% of patients at 2, 3, and 4 years of follow-up. Secondary LOR necessitating commencement of other therapy occurred in a linear fashion at an average annual rate of 9.07% for patients with CD (9.73% for luminal CD) and 8.3% for patients with UC. Interestingly, in the study by Church et al, 22 complete responders with luminal CD experienced a lower LOR at a rate of 2% to 6% per year over 5 years.
In the CD cohort, the only variable that was found to be associated with a reduced hazard of secondary LOR was concomitant therapy with IM for more than 6 months decreasing the rate of LOR by 62%. In addition, when the sample was restricted to patients with luminal disease only, concomitant therapy was again found to reduce the hazard of secondary LOR by 59%. Propensity score matching confirmed that concomitant therapy in the CD cohort was superior to IFX monotherapy in maintaining remission rates at 1 year (78% versus 54%) and 2 years (68% versus 46%) and in overall maintenance of response (secondary LOR at any point during follow-up, 15% versus 49%). In contrast to the CD cohort, no variables in the UC cohort were associated with a reduced hazard of secondary LOR; however, this likely reflects the small sample size examined in this study. Insufficient patient numbers precluded a comparison between AZA and IFX and MTX and IFX.
Similarly, the SONIC trial showed superior 26-and 50-week corticosteroid-free remission rates in adult patients with CD on IFX with AZA compared with IFX alone (56.8% versus 44.4% and 46% versus 34.9%, respectively). 10 Of note, all patients in the SONIC trial were naive to both IFX and IM, an uncommon starting point in routine clinical practice in pediatrics. Although most children with CD have traditionally failed IM therapy before initiation of biologic therapy, 17 an increasing number of children with extensive CD are being initiated on IFX after diagnosis. 21 In our study, we observed no difference in outcomes for patients with CD or UC on concomitant therapy who were naive to IM at IFX induction or following a step-up treatment approach.
The primary reasons for IFX discontinuation despite dose intensification are loss of drug efficacy or development of infusion reactions secondary to IFX antibodies. 34, 35 Studies have shown that low IFX trough levels increase the likelihood of antibody formation. 36, 37 Conversely, concomitant therapy has been associated with higher IFX trough levels, lower likelihood of antibody formation, and subsequent LOR and/or infusion reaction. 10, 14 In our cohort, significantly more patients on IFX monotherapy discontinued IFX because of LOR or experienced infusion reactions secondary to IFX antibodies compared with children on concomitant therapy (55.2% versus 21.1%, P , 0.001).
In patients on maintenance therapy who lose response, IFX dose intensification, including increasing the IFX dose to 10 mg/kg or shortening the infusion interval to every 6 weeks or less has been shown to be an effective strategy to recapture response. 38 Our study also demonstrated clear evidence of successful implementation of this strategy. In the CD cohort, of the 60 patients in whom dose intensification was implemented, response was recaptured in 60% with ongoing response in 97% at 2 years and 96% at 3 years. Similarly, in patients with UC, of the 19 cases in whom dose intensification was implemented, recapturing of response was established in 63% with ongoing response in 100% of patients at 2 and 3 years follow-up.
This study also demonstrated successful recapture of response with adalimumab in patients with secondary LOR and severe infusion reactions to IFX. In the 13 (43%) patients with secondary LOR placed on adalimumab, 77% responded (9/12 CD and 1/1 UC) and were on adalimumab at last follow-up. Similarly, in the 5 (71%) patients with severe infusion reactions, 100% responded (3 CD and 2 UC) and were on adalimumab at last follow-up.
Consistent with published data, IFX was well tolerated. 17, 39, 40 In our cohort, no documented adverse event was reported in 38% of the patient cohort while on IFX. Notably, in patients who had at least 1 documented adverse event, there was no difference in adverse events reported between patients on IFX monotherapy or concomitant therapy (67% versus 60%). Moreover, the most common adverse events were minor including upper respiratory tract infections (37%), minor skin infections (6%), and gastroenteritis (6%). Serious adverse events were reported in 26% of patients with no significant differences reported in patients on monotherapy compared with concomitant therapy (15% versus 11%). During the study, no deaths were reported. One patient on concomitant therapy (with AZA) developed a follicular lymphoma, discontinued concomitant therapy, and was treated with successful tumor excision. Ten years after tumor diagnosis, this patient remains well and without tumor recurrence.
This study demonstrates that IFX therapy is safe, effective, and durable in a pediatric IBD population. Moreover, the study highlights that IFX in combination with an IM was significantly more effective than IFX monotherapy in maintaining steroid-free remission. However, despite the benefits of concomitant therapy, the malignancy risk associated with AZA use remains a concern. [41] [42] [43] [44] [45] [46] Kotlyar et al, 41 in their systematic reviews and meta-analyses of 18 studies including 10 single-center referral centers (n ¼ 4922) and 8 population-based studies (n ¼ 30,204), showed that patients with IBD taking thiopurines had a standardized incidence ratio (SIR) for lymphoma of 4.92 (95% CI, 3.10-7.78). Nevertheless, there was a significant heterogeneity with SIRs ranging from 2.80 (95% CI, 1.82-4.32) in the population-based studies to 9.24 (95% CI, 4.69-18.2) in referral center studies. Notably, analysis of the population studies showed an increased risk among current thiopurine users with an SIR of 5.71 (95% CI, 3.72-10.1) but not former users. Furthermore, a meta-analysis of the CESAME and ENEIDA data reaffirmed that males are at greater risk with approximately twice the relative risk as women. In addition, the analyses showed that patients under 30 years of age had the highest relative risk with an SIR of 6.99 (95% CI, 2.99-16.4). Indeed younger patients, and particularly pediatric patients may become infected with Epstein-Barr virus around the same time that they receive thiopurines. Consequently, this patient group may be at even higher risk for treatment with thiopurines. In addition, there also exists a small but real risk of hepatosplenic T-cell lymphoma, nearly uniformly present in males under 35 years of age. 47 A recent publication in pediatric patients with IBD also examined the frequency of malignancy utilizing data on 5766 patients from the DEVELOP Registry 48 (3857 thiopurine exposed 6 biologics and 1909 thiopurine nonexposed 6 biologics). Fifteen cases of malignancies (9 lymphoid malignancies, 3 solid tumors, and 3 skin malignancies) and 5 cases of hemophagocytic lymphohistiocytosis (HLH) with 24,543 patient-years of followup were identified. No increased risk of malignancy was noted in the IFX cohorts, stratified by thiopurine exposure as well as respective nonbiologic cohorts compared with the Surveillance, Epidemiology, and End Results (SEER) reference population. However, the study did show that patients on any biologic (including IFX) plus thiopurine exposure had a significantly increased risk of malignancy with an SIR of 2.88 (95% CI, 1.44-5.14). Consistent with adult data, analysis of the pediatric population showed an increased risk among current thiopurine users or those who discontinued thiopurines within 1 year with an SIR of 2.43 (CI, 1.29-4.15). This study also highlighted a potential role of thiopurines in the pathogenesis of HLH, as all cases occurred during active thiopurine therapy whereas none had exposure to biologics, or MTX. Notably, 4 cases of HLH were associated with primary Epstein-Barr virus infection and one with presumed primary cytomegalovirus infection. Intriguingly, in contrast to the higher propensity of lymphoma seen in males, 3 cases of HLH were diagnosed in adolescent females. Consequently, both female and male pediatric patients with IBD exposed to thiopurines should be considered at risk for HLH, and viral infections including Epstein-Barr virus and cytomegalovirus infection should be considered. Indeed, studies with larger sample size and longer duration of follow-up in the pediatric IBD population on IFX monotherapy and concomitant therapy are required to fully evaluate the long-term risk of malignancy and HLH.
The recent data in adult studies demonstrating limited effect of thiopurines in changing the natural history of CD, 49, 50 together with the pediatric data which showed no change in growth deficits in children with newly diagnosed CD treated with thiopurines, 51 and the DEVELOP safety data, suggest that when considering thiopurines in patients with IBD, the risk of lymphoma needs to be weighed against the potential benefits.
The ongoing concern of malignancy risk with AZA use together with the increased use of MTX with IFX in pediatric patients with IBD, 5, 11 despite the lack of efficacy of MTX shown in the COMMIT study, 14 suggests that further evaluation in larger prospective pediatric cohorts is urgently needed. Indeed, Hyams et al, 48 using the DEVELOP Registry, evaluated pediatric patients with IBD on MTX with 1509 MTX-exposed patients (977 also had exposure to thiopurines, with only 532 exposed only to MTX in the absence of thiopurines) with 1630.1 patient-years of followup. Comparison of unadjusted incidence rates of malignancy by exposure cohorts demonstrated no increased rates in the MTXexposed cohorts versus the MTX-unexposed cohorts. Moreover, the 6 MTX-exposed patients who developed malignancy also had previous exposure to thiopurines and IFX. Although these data are promising, further larger prospective pediatric cohort studies are required.
It is important to note that our study had several limitations. Our data are reflective of a single Pediatric IBD center, and the study was retrospective and observational in nature without randomization or blinding. However, the cohort was well characterized, care was largely standardized, each infusion was given at our institution, and the patients were extensively followed and reported on. Moreover, these data are similar to what have been reported in the literature by several single-center studies. 5, 15, 20, 22 The smaller sample size in the UC group and the limited number of patients in the whole cohort on concomitant therapy with MTX and variation in MTX dosing limited our power to detect meaningful differences between patients with UC on monotherapy and concomitant therapy and between patients on concomitant therapy with MTX or AZA. Although IFX dose intensification was largely based on clinical indications and biomarkers of inflammation (ESR and CRP), it is important to note that IFX dose intensification recaptured response in at least 60% of cases. The use on IFX trough levels and antibodies to IFX to determine dose intensification or switching out of drug class is being increasingly used in clinical practice; however, the frequency of testing and the trough levels required for drug efficacy during induction and maintenance therapy remain to be determined. Further studies with a more systematic approach to therapeutic drug monitoring are required to optimize dosing regimens. Moreover, maximizing efficacy of biologics through appropriate drug monitoring strategies may minimize the need for concomitant therapy.
In conclusion, our study showed sustained efficacy of IFX in a well-characterized cohort of pediatric patients with IBD with durability of response enhanced by concomitant therapy. However, when considering thiopurines in the management of pediatric patients with IBD, the risk of lymphoma and HLH needs to be weighed against the potential benefits. 
